Back to homepage

Haematology and Oncology

Second-line treatment options in hepatocellular carcinoma

Authors: Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

More

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Authors: Vincenzo Accurso MD, Marco Santoro MD, Salvatrice Mancuso MD, Marisante Napolitano MD, Florinda Di Piazza MD, Antonio Russo MD, Sergio Mario Siragusa MD

This case report presents initial experience with a patient affected by primary myelofibrosis, retreated with ruxolitinib after a 3-month suspension of
therapy due to clinical decision.

More

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

Authors: Shinichi Makita MD, PhD, Katsuaki Imaizumi Ph, Saiko Kurosawa MD, Kensei Tobinai MD, PhD

In this review, the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy are summarized, focusing on B-cell NHL

More

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Authors: Melissa E Badowski PharmD, MPH, Bradley Burton PharmD, Kristy M Shaeer PharmD, MPH, John Dicristofano BS, PharmD Candidate

This article evaluates existing literature through such means as drug databases and package inserts along with PubMed/Medline, Embase, and Google Scholar databases to develop a reference tool for providers to utilize when there is a decision to treat a patient with ART and oral oncolytic agents concurrently.

More

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Authors: Marisa C Liu MD, MPH, Krishnansu S Tewari MD

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

More